// App-Quantinova.ai

: Anticoagulation Prophylaxis with Weight-Adjusted Enoxaparin Reduces Rates of Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy

Researchers

Presenter

  • Hassan Sibai

Principal Investigators

  • Ruiqi Chen

  • Xing Liu

  • Aaron D Schimmer

  • Andre Schuh

  • Arjun Law

  • Caroline J McNamara

  • Dawn Maze

  • Karen W.L. Yee

  • Mark D. Minden

  • Steven M Chan

  • Vikas Gupta

  • Tracy Murphy

  • Umberto Falcone

  • Naoko Sakurai

  • Joseph M. Brandwein

  • Jack Seki

Medical Centers

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • University of Toronto - University Health Network-Princess Margaret Cancer Centre, TORONTO, Canada

  • University of Toronto - University Health Network-Princess Margaret Cancer Centre, TORONTO, Canada

  • Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Princess Margaret Hospital Cancer Program, Toronto, ON, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

  • University of Toronto, Toronto, ON, Canada

  • Division of Hematology, University of Alberta, Edmonton, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Acute lymphoblastic leukemia

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Asparaginase

  • Enoxaparin

  • Enoxaparin sodium

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved